Lonza CD19+/IgD+ Naive B Cells
Human CD19+/IgD+ B cells isolated from peripheral blood using negative immunomagnetic selection, cryopreserved, ≥1 million cells. Catalog #: 4W-602
Product Overview
Leukapheresed CD19+/IgD+ B cells are negatively selected from mononucleated cells using immunomagnetic isolation system to deplete non-naive B cells. Cells are cryopreserved in Lonza Cryo Media in a cryovial. Cell purity is determined post thaw using a FACS assay. Count and viability is determined using AO/PI. Cells are collected from healthy donors following IRB protocols. Manufactured by AllCells®
Applications
Generating antibody libraries
Co-culture with T helper cells or cytotoxic lymphocytes (CTL)
B cell activation, clonal expansion, Ig rearrangement, and Ig secretion
Antigen presenting cell (APC) signal transduction and antigen presentation
Content
1 vial containing ≥ 1 million cryopreserved cells
Recommended Media
Lonza X-VIVO™ 10 with L-glutamine, gentamicin and phenol red
Lonza X-VIVO™ 10 Serum-free Hematopoietic Cell Medium
Lonza X-VIVO™ 15 with L-glutamine, gentamicin, and phenol red
Lonza X-VIVO™ 15 Serum-free Hematopoietic Cell Medium, 500mL
Lonza X-VIVO™ 15 Serum-free Hematopoietic Cell Medium,1L
Lonza X-VIVO™ 15 with with L-glutamine, gentamicin, recombinant transferrin, and phenol red
Catalog #: 4W-602
Please email us at cs@medikonia.com for any enquiry. To place an order, please include the catalog number(s) of the product(s) in the email.